FCCC LOGO Faculty Publications
Katz MH , Shi Q , Ahmad SA , Herman JM , Marsh RW , Collisson E , Schwartz L , Frankel W , Martin R , Conway W , Truty M , Kindler H , Lowy AM , Bekaii-Saab T , Philip P , Talamonti M , Cardin D , LoConte N , Shen P , Hoffman JP , Venook AP
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101
JAMA Surg. 2016 Aug 17;151(8) :e161137
PMID: 27275632    PMCID: PMC5210022    URL: http://www.ncbi.nlm.nih.gov/pubmed/27275632
Back to previous list
Importance: Although consensus statements support the preoperative treatment of borderline resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this strategy have been conducted. Existing studies are retrospective and confounded by heterogeneity in patients studied, therapeutic algorithms used, and outcomes reported. Objective: To determine the feasibility of conducting studies of multimodality therapy for borderline resectable pancreatic cancer in the cooperative group setting. Design, Setting, and Participants: A prospective, multicenter, single-arm trial of a multimodality treatment regimen administered within a study framework using centralized quality control with the cooperation of 14 member institutions of the National Clinical Trials Network. Twenty-nine patients with biopsy-confirmed pancreatic cancer preregistered, and 23 patients with tumors who met centrally reviewed radiographic criteria registered. Twenty-two patients initiated therapy (median age, 64 years [range, 50-76 years]; 55% female). Patients registered between May 29, 2013, and February 7, 2014. Interventions: Patients received modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of external-beam radiation (50.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pancreatectomy. Main Outcomes and Measures: Feasibility, defined by the accrual rate, the safety of the preoperative regimen, and the pancreatectomy rate. Results: The accrual rate of 2.6 patients per month was superior to the anticipated rate. Although 14 of the 22 patients (64% [95% CI, 41%-83%]) had grade 3 or higher adverse events, 15 of the 22 patients (68% [95% CI, 49%-88%]) underwent pancreatectomy. Of these 15 patients, 12 (80%) required vascular resection, 14 (93%) had microscopically negative margins, 5 (33%) had specimens that had less than 5% residual cancer cells, and 2 (13%) had specimens that had pathologic complete responses. The median overall survival of all patients was 21.7 months (95% CI, 15.7 to not reached) from registration. Conclusions and Relevance: The successful completion of this collaborative study demonstrates the feasibility of conducting quality-controlled trials for this disease stage in the multi-institutional setting. The data generated by this study and the logistical elements that facilitated the trial's completion are currently being used to develop cooperative group trials with the goal of improving outcomes for this subset of patients. Trial Registration: clinicaltrials.gov Identifier: NCT01821612.
Katz, Matthew H G Shi, Qian Ahmad, Syed A Herman, Joseph M Marsh, Robert de W Collisson, Eric Schwartz, Lawrence Frankel, Wendy Martin, Robert Conway, William Truty, Mark Kindler, Hedy Lowy, Andrew M Bekaii-Saab, Tanios Philip, Philip Talamonti, Mark Cardin, Dana LoConte, Noelle Shen, Perry Hoffman, John P Venook, Alan P JAMA Surg. 2016 Jun 8:e161137. doi: 10.1001/jamasurg.2016.1137.